Navigation Links
Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial

Pluromed, Inc. has completed enrollment in its LeGoo™ off-pump coronary artery bypass clinical study, based on a protocol reviewed by the U.S. Food and Drug Administration (FDA). When completed, the report of the study will be filed with the FDA as part of the company's submission for U.S. regulatory approval of LeGoo™.

(PRWEB) -- Pluromed, Inc. today announced that it has completed enrollment in its LeGoo™ off-pump coronary artery bypass clinical study, which is evaluating the clinical efficacy of LeGoo™ as compared to a traditional vessel loop. This prospective, randomized trial commenced enrollment in 2008 and has reached its goal of 110 patients, enrolled at 9 hospitals in 4 countries. Principal investigators for the trial were Gerhard Wimmer-Greinecker, M.D., Ph.D., Ardawan Rastan, M.D., Ph.D., Volkmar Falk, M.D., PhD, Olivier Bouchot, M.D., Jan Gummert, M.D., Ph.D., Jean-Philippe Verhoye, M.D., Ph.D., Louis Perrault, M.D., Ph.D., Anno Diegeler, M.D., Ph.D. and Jos G. Maessen, M.D., Ph.D.; Dr. Valavanur A. Subramanian, Chairman of the Department of Cardiothoracic Surgery at The Lenox Hill Heart and Vascular Institute of New-York, served as Chairman of the study’s Data Safety Monitoring Board.

Pluromed’s LeGoo™ is a polymer-based device which is comprised of a non-toxic and biocompatible gel that exists as a liquid at low temperatures and rapidly transitions to a solid at body temperature, forming a plug that can occlude blood vessels. LeGoo™ is injected into a blood vessel that is intended to be occluded, where it stays in a “plug” form for several minutes allowing the surgeon to work in a bloodless field. The gel dissolves with time (spontaneously) or can be reversed back to liquid instantly by cooling the site with ice or irrigating with cold saline. Once dissolved below a minimum concentration, the polymer cannot never re-solidify.

The primary purpose of the study is to demonstrate the clinical safety and efficacy of LeGoo™ in comparison to a standard vessel occlusion method (i.e. vessel loops). Although LeGoo™ is also designed for use in other vascular surgeries where temporary vessel occlusion is desired, this study specifically focuses on the use of LeGoo™ in off-pump coronary bypass (OPCAB, as a most sensitive model of adverse changes that may occur at any vascular site outside of the neurovascular system. The primary endpoint is the proportion of anastomoses (process of suturing the bypass graft to the coronary artery) in which satisfactory hemostasis is achieved.

Dr. William J Cohn, Director of Minimally Invasive Technology at Texas Heart Institute, is the medical director of the study. "With enrollment completed, our focus now turns to data monitoring, completion of follow up and preparation for filing with the U.S. Food and Drug Administration and for primary endpoint publication” said Dr. Cohn. "We are grateful to all the trial investigators who have worked so diligently to reach this milestone."

“This important trial is the latest example of the commitment of leading vascular and cardiovascular surgeons, who seek less traumatic methods to improve patient outcome”, said Jean-Marie Vogel, President and CEO of Pluromed. “We appreciate the participation of the 22 leading physicians and 13 research coordinators, whose efforts led to the successful completion of enrollment."

About Pluromed, Inc.
Pluromed, Inc., Woburn, Massachusetts, founded in 2003, is pioneering the use of atraumatic gel plugs to improve the safety, efficacy and economics of medical interventions. These products potentially address a broad surgery market that includes cardiac and vascular surgery, prostate, kidney and liver surgery, plastic/reconstructive surgery, trauma/battlefield applications and the treatment of kidney stones. They are based on the Company's patented rapid phase transition polymer technology; Pluromed Rapid Transition PolymersÔ (RTP™) are liquid at low temperature and quickly transition to a high viscosity gel at body temperature. Pluromed’s BackStop™, a product used in the treatment of ureteral stones, is cleared for human use in Europe, Canada and the United States. LeGoo™is approved for human use in Europe but is not currently cleared for human use in the USA. For more information, please visit


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pluromed, Inc. Signs Agreement with Boston Scientific
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Good Vibrations Announces Enhanced Education Program
4. Young Innovations, Inc. Announces Record EPS for the Year
5. TeamHealth Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2009 Earnings Release Date and Conference Call
6. Sunquest Announces Significant Speaker Schedule for HIMSS 2010
7. Announces the Addition of Fully Accredited Law and Criminal Justice Degree Programs to its Current Website Offerings
8. Announces Expansion of Liberal Arts & Humanities to its Accredited Online Degree Programs
9. Sinovac Announces Closing of Common Share Offering
10. WellPoint Announces Appearance at Upcoming Conference
11. Healthcare Realty Trust Announces Fourth Quarter Dividend
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge ... imaging in the Waterloo region. Using the Ocean Platform, family physicians can now ... their electronic medical record (EMR) without the need for redundant patient entry or ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... nouvelle approche consistant à combiner l,immunothérapie au traitement ...    --> Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... November 27, 2015 Ein ... fortgeschrittenem Krebs.   --> Ein neuer ... Krebs.   --> Ein neuer ... Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November 2015 ...
Breaking Medicine Technology: